Talk:Atoltivimab/maftivimab/odesivimab

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
High	This article has been rated as High-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Atoltivimab/maftivimab/odesivimab.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Need clarificaton and correction

1. the wordings "due to the treatment's potential to inhibit replication of a live vaccine virus indicated for prevention of Ebola virus infection" seem to imply there had been vaccine for preventing Zaire ebolavirus infection, is it so? and when a person had contracted with the Zaire ebolavirus, why a vaccine is needed? 2. citation used did not support that atoltivimab/maftivimab/odesivimab had an orphan drug designation from European Medicines Agency. Can anybody help? Thanks. ThomasYehYeh (talk) 01:38, 22 November 2024 (UTC)[reply]